627 related articles for article (PubMed ID: 27476706)
21. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for multiple myeloma].
Kosugi H
Rinsho Ketsueki; 2015 Mar; 56(3):279-88. PubMed ID: 25876781
[TBL] [Abstract][Full Text] [Related]
22. Multiple myeloma: an update on biology and treatment.
Ludwig H; Meran J; Zojer N
Ann Oncol; 1999; 10 Suppl 6():31-43. PubMed ID: 10676551
[TBL] [Abstract][Full Text] [Related]
23. Emerging trends in the clinical use of bortezomib in multiple myeloma.
Richardson PG; Schlossman R; Mitsiades C; Hideshima T; Munshi N; Anderson K
Clin Lymphoma Myeloma; 2005 Sep; 6(2):84-8. PubMed ID: 16231845
[TBL] [Abstract][Full Text] [Related]
24. An update of the management of multiple myeloma: the changing landscape.
Reece DE
Hematology Am Soc Hematol Educ Program; 2005; ():353-9. PubMed ID: 16304403
[TBL] [Abstract][Full Text] [Related]
25. Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group.
Quach H; Joshua D; Ho J; Szer J; Spencer A; Harrison S; Mollee P; Roberts A; Horvath N; Talaulikar D; To B; Zannettino A; Brown R; Catley L; Augustson B; Jaksic W; Gibson J; Prince HM
Intern Med J; 2015 Mar; 45(3):335-43. PubMed ID: 25735577
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
[TBL] [Abstract][Full Text] [Related]
27. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
28. Towards Stratified Medicine in Plasma Cell Myeloma.
Egan P; Drain S; Conway C; Bjourson AJ; Alexander HD
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775669
[TBL] [Abstract][Full Text] [Related]
29. Multiple myeloma.
Harousseau JL; Shaughnessy J; Richardson P
Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
[TBL] [Abstract][Full Text] [Related]
30. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
[TBL] [Abstract][Full Text] [Related]
31. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
32. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
33. [New treatment and diagnostic test for multiple myeloma].
Handa H
Rinsho Byori; 2014 Apr; 62(4):337-51. PubMed ID: 25022063
[TBL] [Abstract][Full Text] [Related]
34. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
Dispenzieri A; Rajkumar SV; Gertz MA; Fonseca R; Lacy MQ; Bergsagel PL; Kyle RA; Greipp PR; Witzig TE; Reeder CB; Lust JA; Russell SJ; Hayman SR; Roy V; Kumar S; Zeldenrust SR; Dalton RJ; Stewart AK
Mayo Clin Proc; 2007 Mar; 82(3):323-41. PubMed ID: 17352369
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the management of multiple myeloma.
Kumar L; Verma R; Radhakrishnan VR
Natl Med J India; 2010; 23(4):210-8. PubMed ID: 21192514
[TBL] [Abstract][Full Text] [Related]
36. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
[TBL] [Abstract][Full Text] [Related]
37. Multiple myeloma: from diagnosis to treatment.
Eslick R; Talaulikar D
Aust Fam Physician; 2013 Oct; 42(10):684-8. PubMed ID: 24130968
[TBL] [Abstract][Full Text] [Related]
38. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in the treatment of multiple myeloma.
Henick K; Vescio RA; Berenson JR
Curr Opin Hematol; 1998 Jul; 5(4):254-8. PubMed ID: 9747631
[TBL] [Abstract][Full Text] [Related]
40. The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.
Gay F; Cavallo F; Palumbo A
Drugs; 2015 Mar; 75(4):367-75. PubMed ID: 25764394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
